Document is current
Any future updates will be listed below
-
Authors
Ruder, Samuel https://orcid.org/0000-0003-3676-2798
Ricaurte-Fajardo, Andres https://orcid.org/0000-0002-7374-4460
Sun, Michael
Huicochea Castellanos, Sandra https://orcid.org/0000-0003-2907-8744
Osborne, Joseph R. https://orcid.org/0000-0003-0232-5960
Tagawa, Scott T. https://orcid.org/0000-0003-2777-8587
- License Information
-
More Information
Article History
Accepted: 29 January 2025
First Online: 26 March 2025
Change Date: 8 May 2025
Change Type: Update
Change Details: In the original version of this article, the given and family names of “Sandra Huicochea Castellanos” were incorrectly structured “Sandra Huicochea” as GivenName, “Castellanosas” as FamilyName where it should have been “Sandra” as GivenName, “Huicochea Castellanos” as FamilyName.
Declarations
:
: SR: no conflict of interest. MS: no conflict of interest. ARF: no conflict of interest. SHC: no conflict of interest. JRO: consulting or advisory role: Medscape, UroToday, Siemens Healthineer. Travel, acommodations, expenses: Siemens HealthineersSTT: institutional fees from AbbVie, Ambrx, Amgen, Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Clarity, Clovis, Endocyte, Genentech, Gilead, Inovio, Janssen, Karyopharm, Medivation, Merck, Newlink, Novartis, POINT Biopharma, Rexahn, Sanofi, and Seattle Genetics; and consultant fees from AbbVie, Aikido Pharma, Ambrx, Amgen, Astellas, Bayer, Blue Earth, Clarity Pharma, Clovis, Convergent Therapeutics, Daiichi Sankyo, Eisai, EMD Serono, Genentech, Genomic Health, Janssen, Medivation, Merck, Myovant, Novartis, Pfizer, POINT Biopharma, Regeneron, Sanofi, Seattle Genetics, Telix, Tolmar, and TransThera.
